Expression of CD44s, CD44v3 and CD44v6 in benign and malignant breast lesions: Correlation and colocalization with hyaluronan

Histopathology

Volumn 47, Issue 4, 2005, Pages 420-428

  Auvinen, P ^a   Tammi, R ^b   Tammi, M ^b   Johansson, R ^a   Kosma, Veli Matti ^a,b  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Benign breast lesions; Breast cancer; CD44; Hyaluronan

Indexed keywords

CD44V ANTIGEN; CD44V6 ANTIGEN; HERMES ANTIGEN; HYALURONIC ACID;

ARTICLE; BREAST TUMOR; CARCINOMA CELL; CELL SURFACE; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; STROMA CELL; TUMOR DIFFERENTIATION; UPREGULATION; COMPARATIVE STUDY; METABOLISM; PAGET NIPPLE DISEASE; PATHOLOGY;

ANTIGENS, CD44; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; HUMANS; HYALURONIC ACID; IMMUNOHISTOCHEMISTRY;

EID: 26444490562     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2005.02220.x     Document Type: Article

References (30)

1. Screaton G, Bell M, Jackson D, Cornelis F, Gerth U, Bell J. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc. Natl Acad. Sci. USA 1992; 89; 12160-12164.
2. Underhill C. CD44: The hyaluronan receptor. J. Cell Sci. 1992; 103; 293-298.
3. Ponta H, Wainwright D, Herrlich P. Molecules in focus. The CD44 protein family. Int. J. Biochem. Cell Biol. 1998; 30; 299-305.
4. Jalkanen S, Bargatze R., de los Toyos J, Butcher E. Lymphocyte recognition of high endothelium: antibodies to distinct epitopes of an 85-95-kD glycoprotein antigen differentially inhibit lymphocyte binding to lymph node, mucosal, or synovial endothelial cells. J. Cell Biol. 1987; 105; 983-990.
5. Dall P, Heider K-H, Sinn H-P et al. Comparison of immunohistochemistry and RT-PCR for detection of CD44v-expression, a new prognostic factor in human breast cancer. Int. J. Cancer 1995; 60; 471-477.
6. Kaufmann M, Heider K-H, Sinn H-P, von Mickwitz G, Ponta H, Herrlich P. CD44 variant exon epitopes in primary breast cancer and length of survival. Lancet 1995; 345; 615-619.
7. Foekens J, Dall P, Klijn J et al. Prognostic value of CD44 variant expression in primary breast cancer. Int. J. Cancer 1999; 84; 209-215.
8. Friedrichs K, Franke F, Lisboa BW et al. CD44 isoforms correlate with cellular differentiation but not with prognosis in human breast cancer. Cancer Res. 1995; 55; 5424-5433.
9. Bankfalvi A, Terpe HJ, Breukelmann D et al. Gains and losses of CD44 expression during breast carcinogenesis and tumour progression. Histopathology 1998; 33; 107-116.
10. Joensuu H, Klemi P, Toikkanen S, Jalkanen S. Glycoprotein CD44 expression and its association with survival in breast cancer. Am. J. Pathol. 1993; 143; 867-874.
11. Herrera-Gayol A, Jothy S. CD44 modulates Hs578T human breast cancer cell adhesion, migration, and invasiveness. Exp. Mol. Pathol. 1999; 66; 99-108.
12. Guriec N, Marcellin L, Gairard B et al. CD44 exon 6 expression as a possible early prognostic factor in primary node negative breast carcinoma. Clin. Exp. Metastasis 1996; 14; 434-439.
13. Toole B. Glycosaminoglycans in morphogenesis. In Hay ED ed. Cell biology of the extracellular matrix. New York: Plenum Press 1981; 259-294.
14. Aruffo A, Stamenkovic I, Melnick M, Underbill C, Seed B. CD44 is the principal cell surface receptor for hyaluronate. Cell 1990; 61; 1303-1313.
15. Ohta S, Yoshida J, Iwata H, Hamguchi M. Hyaluronate activates tyrosine phosphorylation of cellular proteins including focal adhesion kinase via CD44 in human glioma cells. Int. J. Oncol. 1997; 10; 561-564.
16. Culty M, Shizari M, Thompson E, Underbill C. Binding and degradation of hyaluronan by human breast cancer cell lines expressing different forms of CD44: correlation with invasive potential. J. Cell Physiol 1994; 160; 275-286.
17. Bartolazzi A, Peach R, Aruffo A, Stamenkovic I. Interactions between CD44 and hyaluronate is directly implicated in the regulation of tumor development. J. Exp. Med. 1994: 180; 53-66.
18. Auvinen P, Parkkinen J, Johansson R et al. Expression of hyaluronan in benign and malignant breast lesions. Int. J. Cancer (Pred. Oncol.) 1997; 74; 477-481.
19. Tammi R, Ågren U, Tuhkanen A-L, Tammi M. Hyaluronan metabolism in skin. Prog. Histochem. Cytochem. 1994; 29; 1-81.
20. Alpaugh M, Maggie L, Nguyen M, Deato M, Dishakjian L, Barsky S. Myoepithelial-specific CD44 shedding contributes to the anti-invasive and antiangiogenic phenotype of myoepithelial cells. Exp. Cell Res. 2000; 261; 150-158.
21. Cooper NL, Bardy P, Bacani J et al. Correlation of CD44 expression with proliferative activity of normal human breast epithelial cells in culture. Breast Cancer Res. Treat. 1998; 50; 143-153.
22. Knudson W, Biswas C, Li X-Q, Nemec R, Toole B. The role and regulation of tumour-associated hyaluronan. In Evered D, Whelan J eds. The biology of hyaluronan. New York: Ciba Found. Symp., Chichester: Wiley 1989; 143, 150-169.
23. Delmage J, Powars D, Jaynes P, Allerton S. The selective suppression of immunogenicity by hyaluronic acid. Ann. Clin. Lab. Sci. 1986; 16; 628-639.
24. Misra S, Ghatak S, Zoltan-Jones A, Toole B. Regulation of multidrug resistance in cancer cells by hyaluronan. J. Biol. Chem. 2003; 278; 25285-25288.
25. Koochekpour S, Pilkington G, Merzak A. Hyaluronic acid/CD44H interaction induces cell detachment and stimulates migration and invasion of human glioma cells in vitro. Int. J. Cancer 1995; 63; 450-454.
26. Ward J, Huang L, Guo H, Ghatac S, Toole B. Pertubation of hyaluronan interactions inhibits malignant properties of glioma cells. Am. J. Pathol. 2003; 162; 1403-1409.
27. Zeng C, Toole B, Kinney S, Kuo J, Stamenkovic I. Inhibition of tumor growth in vivo by hyaluronan oligomers. Int. J. Cancer 1998; 77; 396-401.
28. Auvinen P, Tammi R, Parkkinen J et al. Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival. Am. J. Pathol. 2000; 156; 529-536.
29. Williams C, Leek R, Robson A et al. Absence of lymphangiogenesis and intratumoural lymph vessels in human metastatic breast cancer. J. Pathol. 2003; 200; 195-206.
30. Bullard K, Kim H-R, Wheeler M et al. Hyaluronan synthase-3 is upregulated in metastatic colon carcinoma cells and manipulation of expression alters matrix retention and cellular growth. Int. J. Cancer 2003; 107; 739-746.